journal
https://read.qxmd.com/read/37600851/peripheral-hemorrhagic-chorioretinopathy-differentiating-features-from-choroidal-melanoma
#21
JOURNAL ARTICLE
Guneet S Sodhi, Nakul Singh, Jacquelyn Wrenn, Arun D Singh
INTRODUCTION: Peripheral exudative hemorrhagic chorioretinopathy (PEHCR) is one of the leading mimickers of choroidal melanoma because of overlapping features with choroidal melanoma that make the distinction between these two entities difficult. METHODS: To identify nonoverlapping diagnostic features between PEHCR and choroidal melanoma, a retrospective study of 80 patients (80 eyes); 40 patients (40 eyes) with PEHCR; and 40 patients (40 eyes) with choroidal melanoma was conducted...
August 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/37600850/response-to-cook-and-alsina-s-letter-to-editor-reply-to-augsburger-et-al
#22
JOURNAL ARTICLE
James J Augsburger, Cassandra C Skinner, Zelia M Correa
No abstract text is available yet for this article.
August 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/37600849/reply-to-augsburger-et-al-selection-bias-may-impact-reported-metastasis-risk-for-15-gene-expression-profile-class-1a-b-patients
#23
JOURNAL ARTICLE
Robert W Cook, Katherina M Alsina
No abstract text is available yet for this article.
August 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/37600848/angiographic-features-of-iris-melanocytic-tumors-nevus-versus-melanoma
#24
JOURNAL ARTICLE
Janani Singaravelu, Alexander Melendez-Moreno, Jacquelyn Wrenn, Arun D Singh
INTRODUCTION: Determining the nature of iris melanocytic tumors based on clinical exam alone remains challenging. Tumor-associated vasculature of iris melanocytic lesions may facilitate the ability to discern between iris nevus and melanoma. METHODS: In a single-institution, retrospective, observational study of 45 patients with pathologically confirmed iris melanoma and 15 patients with iris nevi that were either clinically stable or pathologically confirmed were included...
August 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925734/a-case-series-of-aggressive-orbital-plasmacytomas
#25
Nizma Permaisuari, Neni Anggraini, Mutmainah Mahyuddin, Evelina Kodrat, Wulyo Rajabto
PURPOSE: Orbital plasmacytoma is a tumor of plasma cells located in the orbit, which is uncommon and only accounts for less than 1% of total orbital tumors. Sixty-five percent of orbital plasmacytoma are carrying a diagnosis of multiple myeloma. We hereby present two aggressive orbital plasmacytoma cases, a rare orbital malignancy with unsatisfactory outcomes. METHODS: This is a series of two orbital plasmacytoma cases. Both initial complaints were unilateral rapid onset of non-axial proptosis with palpable mass in the superior orbit...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925733/recurrence-of-primary-acquired-melanosis-and-conjunctival-intraepithelial-neoplasia
#26
JOURNAL ARTICLE
Karin Svedberg
INTRODUCTION: The aim of this study was to investigate the frequency of recurrences, time to recurrence, and which patients had a recurrence after treatment of conjunctival intraepithelial neoplasia (CIN), carcinoma in situ, and primary acquired melanosis (PAM) with atypia. METHODS: A retrospective chart review of all patients included in the follow-up program after completion of treatment for CIN or PAM with atypia on October 18, 2021, at the Department of Ophthalmology, Sahlgrenska University Hospital, was conducted...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925732/comparative-metastatic-rates-in-gep-class-1a-versus-1b-posterior-uveal-melanoma-results-contrary-to-expectations
#27
JOURNAL ARTICLE
James J Augsburger, Cassandra C Skinner, Zelia M Correa
PURPOSE: The purpose of this study was to determine whether the metastatic rates in patients with gene expression profile (GEP) class 1A versus 1B posterior uveal malignant melanoma supported or contradicted predictions of very low metastatic rate in GEP 1A cases and moderate rate in GEP 1B cases. PATIENTS/METHODS: 164 patients with a cytopathologically confirmed primary posterior uveal malignant melanoma classified by GEP testing as class 1 (100 GEP 1A, 64 GEP 1B) were evaluated...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925731/serous-choroidal-detachment-and-scleritis-associated-with-necrotic-choroidal-tumors
#28
Jared J Ebert, Maura Di Nicola, Eric D Hansen, Sean M Collon, Matthew C Hagen, Basil K Williams
PURPOSE: The aim of the study was to describe choroidal detachments and concurrent scleritis associated with necrotic choroidal metastasis or melanoma. METHODS: We conducted a retrospective case series. RESULTS: We report 4 patients with scleritis and choroidal detachment with an underlying malignant choroidal tumor. All patients underwent fine-needle aspiration biopsy for cytopathologic characterization of their choroidal tumor, and they all demonstrated evidence of tumor necrosis...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925730/outcomes-of-second-line-intravitreal-anti-vegf-switch-therapy-in-radiation-retinopathy-secondary-to-uveal-melanoma-moving-from-bevacizumab-to-aflibercept
#29
JOURNAL ARTICLE
Ojas Srivastava, Ezekiel Weis
INTRODUCTION: Radiation retinopathy is a dose-dependent complication of the retina following exposure to ionizing radiation. The objective of this prospective case series is to determine the clinical efficacy of intravitreal aflibercept for radiation retinopathy secondary to radiotherapy for uveal melanoma in those that failed intravitreal bevacizumab treatment. METHODS: A case series of 30 patients with a mean age of 57 ± 15 years with radiation retinopathy were enrolled...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925729/solitary-metastases-presentation-from-uveal-melanoma-report-of-3-cases-and-a-comprehensive-review-of-the-literature
#30
JOURNAL ARTICLE
Patrícia M Pereira, Ana Luís, Maria José Passos, Emanuel Gouveia
INTRODUCTION: Uveal melanoma (UM) is a rare condition accounting for only 5% of all primary melanoma cases. Still, it is the most frequently diagnosed primary intraocular malignant tumor in adults. UM is an aggressive malignancy that originates from melanocytes in the eye. UMs are usually initiated by a mutation in GNAQ or GNA11 , and rarely harbor a BRAF or NRAS mutations like cutaneous melanomas. Even if the primary tumor has been successfully treated with radiation or surgery, up to half of all UM patients will eventually develop metastatic disease...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925728/local-recurrence-in-choroidal-melanomas-following-robotic-assisted-radiosurgery-cyberknife
#31
JOURNAL ARTICLE
Valerie Schmelter, Frederick Schneider, Stefanie R Guenther, Christoph Fuerweger, Alexander Muacevic, Siegfried G Priglinger, Raffael Liegl, Paul Foerster
INTRODUCTION: Tumor recurrence in choroidal melanoma has been associated with decreased overall survival due to metastatic spreading. To detect risk factors of local recurrence and side effects, we analyzed tumor planning and treatment parameters in patients with recurrence of choroidal melanoma after treatment with robotic-assisted radiosurgery (CyberKnife). METHODS: Six hundred ninety-four patients treated with CyberKnife between 2005 and 2019 were retrospectively reviewed...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/36925727/anterior-uveal-melanocytoma-role-of-diagnostic-fnab
#32
JOURNAL ARTICLE
Alexander Melendez-Moreno, Janani Singaravelu, Jennifer Brainard, Jacquelyn M Davanzo, Arun D Singh
INTRODUCTION: Anterior uveal melanocytoma (AUM) pose a diagnostic challenge as they can mimic growing melanomas. Establishing a definitive diagnosis of melanocytoma necessitates cytologic or histopathologic confirmation. We describe the clinical presentation and characteristics of fifteen pathologically proven AUM cases and assess the role of fine needle aspiration biopsy (FNAB) as a safe and effective tool for diagnosis. METHODS: Retrospective review of pathologically confirmed AUM cases was performed...
February 2023: Ocular Oncology and Pathology
https://read.qxmd.com/read/37431398/predictors-of-local-recurrence-and-progression-free-survival-in-iodine-125-brachytherapy-treated-uveal-melanomas-a-modern-institutional-study
#33
JOURNAL ARTICLE
Aaron A Gurayah, Vanessa A Peters, William Jin, Karthik Kalahasty, Deukwoo Kwon, Wei Zhao, Nirav V Patel, Arnold M Markoe, Zelia M Correa, Matthew T Studenski, J William Harbour, Stuart E Samuels
INTRODUCTION: Iodine-125 brachytherapy is an effective eye-sparing treatment for uveal melanoma. Previous work has shown that uveal melanomas cluster into distinct molecular classes based on gene expression profiles - discriminating low-grade from high-grade tumors. Our objective was to identify clinical and molecular predictors of local recurrence (LR) and progression-free survival (PFS). METHODS: We constructed a retrospective database of uveal melanoma patients from the University of Miami's electronic medical records that were treated between January 8, 2012, and January 5, 2019, with either COMS-style or Eye Physics plaque...
November 2022: Ocular Oncology and Pathology
https://read.qxmd.com/read/36938378/uveitic-granulomas-masquerading-as-ocular-tumors
#34
JOURNAL ARTICLE
Abdulrahman AlZaid, Moustafa S Magliyah, Yahya AlZahrani, Hani Basher ALBalawi, Hassan AlDhibi
INTRODUCTION: Solitary uveal lesions confer a diagnostic challenge to ophthalmologists. Uveitic lesions most abundantly appear amelanotic and commonly involve the choroid. Most amelanotic choroidal lesions are either neoplastic or inflammatory in origin. In our study, we aimed to describe six uveitic granuloma cases, which were referred to a tertiary ophthalmology center as intraocular tumors. METHODS: Retrospective chart review of 6 patients (7 eyes) who had uveitic granulomas and were referred to a tertiary ophthalmology center as having intraocular tumors...
November 2022: Ocular Oncology and Pathology
https://read.qxmd.com/read/36938377/long-term-results-after-intraocular-surgery-in-treated-retinoblastoma-eyes
#35
JOURNAL ARTICLE
Philipp Rating, Norbert Bornfeld, Sabrina Schlüter, Henrike Westekemper, Tobias Kiefer, Martin Stuschke, Sophia Göricke, Petra Ketteler, Saskia Ting, Klaus A Metz, Nikolaos E Bechrakis, Eva Biewald
Introduction: The aim of the study was to analyze the results of intraocular surgery in treated retinoblastoma eyes and to assess the long-term results with a priority on local recurrences, secondary enucleation, and metastases. Methods: Retrospective noncomparative case series. Results: From March 1964 to January 2020, 42 eyes of 40 retinoblastoma patients underwent intraocular surgery. Time interval between the last therapy and surgery was 9.5 years (mean: 114 months; median: 54.5 months). 31 eyes were treated for radiogenic cataract formation with a gain in visual acuity of 61...
November 2022: Ocular Oncology and Pathology
https://read.qxmd.com/read/36938376/clinicopathological-presentation-of-retinoblastoma-in-ethiopia
#36
JOURNAL ARTICLE
Sadik Taju Sherief, Daniel Getaneh Mulatu, Fran Wu, Jacquelyn O'Banion, Helen Dimaras
Introduction: The presenting symptoms of retinoblastoma in Ethiopia, as well as their relationship to the stage of the disease, are poorly understood, but they could be important as background knowledge for creating early detection initiatives. This study aimed to describe the clinical and histopathological characteristics of retinoblastoma among Ethiopian patients. Methods: A hospital-based cross-sectional analysis of all children with newly diagnosed retinoblastoma during the study period of May 2015 to December 2019, inclusive, who presented to a tertiary referral center during were included...
November 2022: Ocular Oncology and Pathology
https://read.qxmd.com/read/36938375/post-brachytherapy-pigment-dispersion-in-uveal-melanoma
#37
JOURNAL ARTICLE
Mahesh Palanivelu Shanmugam, Shwetha Suryakanth, Rajesh Ramanjulu, Divyansh Kailash Chandra Mishra
No abstract text is available yet for this article.
November 2022: Ocular Oncology and Pathology
https://read.qxmd.com/read/36938374/emerging-new-therapeutics-for-retinoblastoma
#38
REVIEW
Vishal Raval, Manoj Parulekar, Arun D Singh
Background: Over the last few decades, chemotherapy has become the main treatment of retinoblastoma, delivered through various routes: intravenous, intra-arterial, and intravitreal. Despite its efficacy, chemotherapy-related toxicity (ocular and systemic) and recurrences due to resistant tumor clones are common, highlighting the need for novel therapeutic agents. Summary: Recent advances in our understanding of the molecular drivers of Rb1 tumorigenesis and mechanisms of tumor resistance have afforded opportunities to explore novel targets such as the MDMX-p53 pathway (nutlin-3), histone deacetylase inhibitors, spleen tyrosine kinase inhibitors, and genetic and immune modulatory drugs...
November 2022: Ocular Oncology and Pathology
https://read.qxmd.com/read/36923229/comparison-of-tumor-size-and-gene-expression-at-presentation-in-uveal-melanoma-patients-before-and-during-the-covid-19-pandemic
#39
JOURNAL ARTICLE
Naomi Hasegawa, Alexander Rusakevich, Eric Bernicker, Bin S Teh, Amy Schefler
Introduction: The aim of this study was to compare the clinical and gene expression variables of uveal melanoma patients presenting before and after the start of the COVID-19 pandemic as surrogate markers in order to assess the pandemic's potential impact on care. Methods: We conducted a retrospective chart review of uveal melanoma patients at Retina Consultants of Texas and assessed tumor size, staging, and gene expression data during two time periods: May 2019 to February 2020 (Group 1: Before the COVID-19 pandemic declaration by the WHO in March 2020) and May 2020 to March 2021 (Group 2: After the start of the COVID-19 pandemic)...
November 2022: Ocular Oncology and Pathology
https://read.qxmd.com/read/35959161/the-histopathology-of-two-eyes-enucleated-after-continuous-transscleral-and-micropulse-transscleral-cyclophotocoagulation-for-refractory-secondary-glaucoma
#40
Imani M Williams, Vamsee K Neerukonda, Anna M Stagner
INTRODUCTION: Cyclodestructive procedures, which target the nonpigmented epithelium of the ciliary body, have been utilized to treat recalcitrant glaucoma since the early 1930s. There are now various types of cyclophotocoagulation (CPC) available. The authors provide a retrospective description that details the histopathologic findings in 2 patients who underwent CPC for uncontrolled uveitic and neovascular glaucoma (NVG) with subsequent enucleation. CASE PRESENTATIONS: Two enucleated globes from 2 patients with secondary refractory glaucoma underwent cilioablative therapy: one with uveitic glaucoma and a remote history of micropulse transscleral CPC (MP-TSCPC) and the other with NVG and a recent history of traditional continuous transscleral CPC (CW-TSCPC)...
June 2022: Ocular Oncology and Pathology
journal
journal
50139
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.